MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 & CD86

CD80的功能分化机制

基本信息

  • 批准号:
    6349888
  • 负责人:
  • 金额:
    $ 30.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-02-01 至 2005-01-31
  • 项目状态:
    已结题

项目摘要

The biological rationale for the expression of two co-stimulatory molecules (CD80 and CD86) on the membrane of professional APC is not clear. Many results demonstrate that both molecules provide equivalent co-stimulatory signals to T-cells. Different roles for CD80 and CD86 in the activation of distinct subpopulations of T-cells have also been described in both in vivo and in vitro models. Our published data along with other results indicate that CD86, but not CD80, stimulates cellular immune responses during DNA vaccination of mice. The important question is why CD86, but not CD80 is required for augmentation of T-cell response after vaccination? Based on our results we suggest several mechanisms to explain these cell responses after vaccination? Based on our results we suggest several mechanisms to explain these functional differences between CD80 and CD86 molecules. First, expression of MHC class I and CD86, but not CD80 along with immunogen may induce local invasion of immunocompetent cells crucial for generation of immune responses. Second, CD80 and CD86 may activate different subpopulations of T-cells. Third, the triggering of receptors with CD80 and CD86 molecules may supply different signals to T-cells. Finally, the ligation of CD86, but not CD80 on the surface of APC could provide important signal to these cells and in turn induce production of certain molecules such as cytokines/lymphokines/chemokines, which are important for T cell activation. To evaluate these hypotheses we propose using DNA immunization as a model system to investigate the following: 1.) The differential effects of CD80 and CD86 expression in the microenvironment of MHC class I positive or negative muscle tissues (i.e. the invasion of immunocompetent cells at the site of DNA inoculation). 2). The activation of different subsets of CTL (CD4+ or C8+) and T helper cells (Th1 or Th2) after co-immunization with immunogen and CD80/CD86 expressing plasmids. 3). The functional region/s of human CD86 molecule involved in enhancement of cellular immune responses after co-immunization with DNA encoding immunogen and different CD80/CD86 mutant molecules. 4) The synergistic effect of co- stimulatory molecules and cytokines produced by professional APC, on T-cell activation after DNA vaccination. 5). The differential expression of genes after ligation of CD86 versus CD80 on muscle cells and professional APC.
在专职APC的膜上表达两种共刺激分子(CD 80和CD 86)的生物学原理尚不清楚。许多结果表明,这两种分子提供等效的共刺激信号的T细胞。在体内和体外模型中也描述了CD 80和CD 86在不同T细胞亚群活化中的不同作用。我们发表的数据沿着其他结果表明,在小鼠DNA疫苗接种期间,CD 86而不是CD 80刺激细胞免疫应答。重要的问题是为什么CD 86,而不是CD 80是疫苗接种后T细胞反应增强所必需的?根据我们的研究结果,我们提出了几种机制来解释这些细胞接种疫苗后的反应?基于我们的研究结果,我们提出了几种机制来解释这些CD 80和CD 86分子之间的功能差异。首先,I类MHC和CD 86的表达,而不是CD 80沿着免疫原的表达,可能诱导对产生免疫应答至关重要的免疫活性细胞的局部侵袭。其次,CD 80和CD 86可以激活不同的T细胞亚群。第三,CD 80和CD 86分子对受体的触发可能向T细胞提供不同的信号。最后,APC表面上的CD 86而不是CD 80的连接可以向这些细胞提供重要的信号,并且反过来诱导某些分子如细胞因子/淋巴因子/趋化因子的产生,这些分子对于T细胞活化是重要的。为了评估这些假设,我们提出使用DNA免疫作为模型系统来研究以下内容:1. CD 80和CD 86表达在MHC I类阳性或阴性肌肉组织的微环境中的差异效应(即免疫活性细胞在DNA接种部位的侵入)。2)。免疫原和CD 80/CD 86表达质粒联合免疫后不同亚群的CTL(CD 4+或C8+)和辅助性T细胞(Th 1或Th 2)的活化。3)。人CD 86分子的功能区参与免疫原编码DNA与不同CD 80/CD 86突变体分子共免疫后细胞免疫应答的增强。4)由专职APC产生的共刺激分子和细胞因子对DNA疫苗接种后T细胞活化的协同作用。5)。肌细胞和专职APC上CD 86与CD 80连接后基因的差异表达。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael G Agadjanyan其他文献

Expression of the Epigenetic factor BORIS (CTCFL) in the Human Genome
  • DOI:
    10.1186/1479-5876-9-213
  • 发表时间:
    2011-12-01
  • 期刊:
  • 影响因子:
    7.500
  • 作者:
    Rosalia de Necochea-Campion;Anahit Ghochikyan;Steven F Josephs;Shelly Zacharias;Erik Woods;Feridoun Karimi-Busheri;Doru T Alexandrescu;Chien-Shing Chen;Michael G Agadjanyan;Ewa Carrier
  • 通讯作者:
    Ewa Carrier

Michael G Agadjanyan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael G Agadjanyan', 18)}}的其他基金

Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial
为 1 期试验生产新批次 AV-1959D 药品和安慰剂
  • 批准号:
    10732215
  • 财政年份:
    2022
  • 资助金额:
    $ 30.64万
  • 项目类别:
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
首个人类 Aβ DNA 疫苗的安全性/耐受性/免疫原性,AV-1959D 在早期 AD 受试者中的 1 期试验:基于 FDA 批准的 IND18953。
  • 批准号:
    10340654
  • 财政年份:
    2022
  • 资助金额:
    $ 30.64万
  • 项目类别:
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
首个人类 Aβ DNA 疫苗的安全性/耐受性/免疫原性,AV-1959D 在早期 AD 受试者中的 1 期试验:基于 FDA 批准的 IND18953。
  • 批准号:
    10571883
  • 财政年份:
    2022
  • 资助金额:
    $ 30.64万
  • 项目类别:
Manufacturing of Drug Product, Dual Aβ/tau Vaccine for Clinical Trials
药品生产,用于临床试验的双重 Aβ/tau 疫苗
  • 批准号:
    10667237
  • 财政年份:
    2019
  • 资助金额:
    $ 30.64万
  • 项目类别:
Evaluation of Safe and Immunogenic Dose of AD Vaccine in aged non-human primates: Prelude to Phase 1 Preventive Vaccinations
AD 疫苗在老年非人灵长类动物中的安全和免疫原性剂量评估:第一阶段预防性疫苗接种的前奏
  • 批准号:
    10433497
  • 财政年份:
    2019
  • 资助金额:
    $ 30.64万
  • 项目类别:
Cooperative program U01 AG060965 Supplement: "Preparation of IND for Dual Aβ/Tau AD Vaccine for submission to FDA"
合作计划 U01 AG060965 补充:“双 Aβ/Tau AD 疫苗 IND 的准备以提交给 FDA”
  • 批准号:
    10505652
  • 财政年份:
    2019
  • 资助金额:
    $ 30.64万
  • 项目类别:
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
抗 Tau AD 疫苗 1 期试验的 IND 临床前研究
  • 批准号:
    10364623
  • 财政年份:
    2019
  • 资助金额:
    $ 30.64万
  • 项目类别:
Repurposing of Universal and Immunogenic MultiTEP Platform Designed for AD to Develop SARS-CoV-2 Multiepitope Vaccine
重新利用专为 AD 设计的通用和免疫原性 MultiTEP 平台来开发 SARS-CoV-2 多表位疫苗
  • 批准号:
    10162389
  • 财政年份:
    2019
  • 资助金额:
    $ 30.64万
  • 项目类别:
Combining AD Epitope Vaccine with Innate Immunity
AD表位疫苗与先天免疫相结合
  • 批准号:
    9439835
  • 财政年份:
    2017
  • 资助金额:
    $ 30.64万
  • 项目类别:
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND
临床前研究以满足 FDA 完成 AV-1959 IND 的要求
  • 批准号:
    8887223
  • 财政年份:
    2015
  • 资助金额:
    $ 30.64万
  • 项目类别:

相似海外基金

Elucidating a molecular understanding of ILC2 MHC class I antigen cross priming
阐明 ILC2 MHC I 类抗原交叉引发的分子理解
  • 批准号:
    486527
  • 财政年份:
    2022
  • 资助金额:
    $ 30.64万
  • 项目类别:
    Studentship Programs
Restoring MHC class I antigen presentation to enhance anti-tumour immunity
恢复MHC I类抗原呈递,增强抗肿瘤免疫力
  • 批准号:
    nhmrc : GNT1164054
  • 财政年份:
    2020
  • 资助金额:
    $ 30.64万
  • 项目类别:
    Project Grants
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
  • 批准号:
    8996707
  • 财政年份:
    2014
  • 资助金额:
    $ 30.64万
  • 项目类别:
Ubiquitin conjugation and direct MHC class I antigen presentation
泛素结合和直接 MHC I 类抗原呈递
  • 批准号:
    8880646
  • 财政年份:
    2014
  • 资助金额:
    $ 30.64万
  • 项目类别:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
  • 批准号:
    9206412
  • 财政年份:
    2014
  • 资助金额:
    $ 30.64万
  • 项目类别:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
  • 批准号:
    8723605
  • 财政年份:
    2014
  • 资助金额:
    $ 30.64万
  • 项目类别:
MHC Class I Antigen Presentation in Viral Infections
病毒感染中 MHC I 类抗原呈递
  • 批准号:
    8072956
  • 财政年份:
    2010
  • 资助金额:
    $ 30.64万
  • 项目类别:
The function of the Ubiquitin-Proteasome-System (UPS) in MHC class I antigen processing in target cells and maturing human dendritic cells (hDCs).
泛素蛋白酶体系统 (UPS) 在靶细胞和成熟人树突细胞 (hDC) 中 MHC I 类抗原加工中的功能。
  • 批准号:
    105348415
  • 财政年份:
    2009
  • 资助金额:
    $ 30.64万
  • 项目类别:
    Research Grants
In vivo analysis of the imnportance of proteasome immunosubunits and of PA28 for MHC class I antigen processing, CTL response induction and tumor-virus elimination (A 7)
体内分析蛋白酶体免疫亚基和 PA28 对于 MHC I 类抗原加工、CTL 反应诱导和肿瘤病毒消除的重要性 (A 7)
  • 批准号:
    5354871
  • 财政年份:
    2002
  • 资助金额:
    $ 30.64万
  • 项目类别:
    Collaborative Research Centres
MHC Class I Antigen Presentation in Viral Infections
病毒感染中 MHC I 类抗原呈递
  • 批准号:
    7991835
  • 财政年份:
    2001
  • 资助金额:
    $ 30.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了